Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA - A pilot study

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 1087-1092

  Arsov, Christian ^a   Quentin, Michael ^a   Rabenalt, Robert ^a   Antoch, Gerald ^a   Albers, Peter ^a   Blondin, Dirk ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Functional mri; Prostate cancer; PSA; Targeted biopsy; Transrectal ultrasound biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REPEAT PROCEDURE; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; BIOPSY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84858770397     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T and Zattoni F: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59: 61-71, 2011.
2. Keetch DW, Catalona WJ and Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571-1574, 1994. (Pubitemid 24151304)
3. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA and Andriole GL: Measurement of prostatespecific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
4. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKemion JB, Ratliff TL, Kavoussi LR and Dalkin BL: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994. (Pubitemid 24121936)
5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M1 Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ and Auvinen A: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328, 2009.
6. Heijmink SW, van Moerkerk H, Kiemeney LA, Witjes JA, Frauscher F and Barentsz JO: A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol 16: 927-938, 2006. (Pubitemid 43380253)
7. Stewart CS, Leibovich BC, Weaver AL and Lieber MM: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166: 86-91, 2001. (Pubitemid 32565349)
8. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC and Marberger M: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop? J Urol 166: 1679-1683, 2001.
9. Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ and Soloway MS: Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology 72: 177-182, 2008.
10. Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V and Witjes JA: Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 59: 962-977, 2011.
11. Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, Corvin S, Sievert KD, Claussen CD, Stenzl A and Schlemmer HP: MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 50: 738-748, 2006.
12. Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP and Schilling D: MRl-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol, 2011 Apr 22. [Epub ahead of print].
13. Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, Huppertz A, Miller K, Strecker R and Hamm B: Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding - multiparametric MR imaging for detection and biopsy planning. Radiology 259: 162-172, 2011.
14. Engelhard K, Hollenbach HP, Kiefer B, Winkel A, Goeb K and Engehausen D: Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol 16: 1237-1243, 2006. (Pubitemid 43834709)
15. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, van Oort IM, Witjes JA, Fütterer JJ and Barentsz JO: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 183: 520-527, 2010.
16. McNeal JE: The zonal anatomy of the prostate. Prostate 2: 35-49, 1981.
17. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974, 1998. (Pubitemid 28445094)
18. Park BK, Kim B, Kim CK, Lee HM and Kwon GY: Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr 31: 534-538, 2007. (Pubitemid 47457665)
19. Littrup PJ: Imaging and prostate cancer chemoprevention: Current diagnosis and future directions. Urology 57: 121-123, 2001.
20. Delongchamps NB and Haas GP: Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol 6: 645-652, 2009.
21. Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W and Wallner K: Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 52: 715-723, 2007.
22. Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, Butler WM, Adamovich E and Wallner KE: Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 13: 71-77, 2010.
23. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, and van der Kwast TH: The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60: 291-303, 2010.
24. Xu S, Kruecker J, Turkbey B, Glossop N, Singh AK, Choyke P, Pinto P and Wood BJ: Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg 13: 255-264, 2008.
25. Singh AK, Kruecker J, Xu S, Glossop N, Guion P, Ullman K, Choyke PL and Wood BJ: Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int 101: 841-845, 2008. (Pubitemid 351347719)
26. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J and Emberton M: Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59: 477-494, 2011.